. Author manuscript; available in PMC: 2012 Jan 1.

Published in final edited form as: J Allergy Clin Immunol. 2011 Jan;127(1):161–166.e1. doi: 10.1016/j.jaci.2010.10.035

Table 2.

Comparison of demographic and outcome features between fluticasone and montelukast

Variable	Fluticasone (n=79)	Montelukast (n=75)	P Value
Age in years (mean± SD)	9.7± 2.2	9.7± 2.2	0.94 ^a
Sex
Male, n (%)	47 (59)	48 (64)	0.57 ^b
Female, n (%)	32 (41)	27 (36)
Height increase in cm (SD)	5.4 (1.8)	5.8 (1.9)	0.16 ^a
Baseline FEV₁, mean (SD)	1.86 (0.56)	1.96 (0.53)	0.24 ^a
Baseline eNO, ppb, median (Quartile 1, Quartile 3)	24.5(13.0,48.5)	29.4(12.7,55.4)	0.82 ^c
Baseline Methacholine PC₂₀, mg/mL, median (Quartile 1, Quartile 3)	0.76(0.27,2.81)	0.85(0.28,2.57)	0.95 ^c
Outcomes (mean ± SD)
Treatment Exposure days	336±17.6	338±19.8	0.49 ^a
Asthma control days during study period	210±97	170±90	0.009 ^a
Percentage with an increase of FEV₁≥12%	73	41	<.001 ^b
Number of exacerbations	0.66±0.9	1.13±1.1	0.002 ^d
Emergency department visits	0.10±0.3	0.35±0.6	0.002 ^d
Physician office visits	2.19±1.9	2.08±1.8	0.64 ^d
Hospital days	0	0	N/A
Missed school days	1.4±2.5	2.1±3.1	<.001 ^d
Missed work days	0.6±1.5	0.8±1.9	0.06 ^d

by two-sample t-tests for difference in mean.

by two-sample z-tests for proportions.

by the Mann-Whitney U test for difference in median.

by simple Poisson regression with the treatment group as the predictor.